

## **Detection of extended-spectrum $\beta$ -lactamases in clinical isolates of *E. coli* and *klebsiella* species from Udaipur Rajasthan**

**Sushil Kumar Sahu, A. S. Dalal, G. Bansal**

Department of Microbiology, R.N.T. Medical college, Udaipur, Rajasthan, India

### **Abstract**

The continued emergence of ESBLs presents diagnostic challenges to the clinical microbiology laboratories, which should be aware of the need for their detection by accurately identifying the enzymes in clinical isolates. The importance of the infections due to Extended-Spectrum  $\beta$ -Lactamase-producing *Escherichia coli* and *Klebsiella* species (ESBL-EK) has been increasingly recognized in recent years. ESBL-EK infections are of clinical concern, because few antimicrobials are available as therapeutic options. Efforts to maintain current therapeutic option for such infections are essential. Total 200 screened isolation of *E. coli* and *Klebsiella* species obtained from June 2006 to 31<sup>st</sup> December 2007 from 3146 various clinical samples such as pus; urine, blood, CSF, ear discharge, pleural fluid & sputum were included in the study. All isolates were identified and confirmed by standard conventional methods. Isolates with resistance or decreased susceptibility to third generation cephalosporins (as per the criteria of NCCLS guidelines by Kirby-Bauer methods) were selected as ESBL producers. ESBL production where detected by Double disk synergy test (DDST) and Inhibitory Potentiated disk diffusion test (IPDDT). Of the 200 isolates, 117(58.5 %), 83(41.5%) were identified as *E.coli* and *Klebsiella* respectively and showed maximum resistance against Cefpodoxime (100%). By DDST test 92.6% & 89.1%, 66.7% & 71.7%, 88.8% & 71.7% showed synergy between Cefotaxime, Ceftriaxone with Clavulanic acid by *Klebsiella* species and *E.coli* respectively. The incidence of ESBLs among *E. coli* and *Klebsiella* species were 44.4% (52) & 36.1% (30) respectively by IPDDT test and detect an additional 4.5%(9) ESBL isolates than DDST test. Medicine 56.1% & 44.8% and Surgery 21% & 31% wards showed maximum percentage of ESBLs producers *E. coli* and *Klebsiella* respectively. ESBL-producing *E. coli* and *Klebsiella* species infections have a significant impact on several important clinical outcomes and efforts to control outbreaks of such infections should emphasize judicious use of all antibiotics as well as barrier precautions to reduce spread.

**Key words:** Extended-spectrum  $\beta$ -lactamases, therapeutic, isolation, double disk synergy test

*Accepted May 21 2011*

### **Introduction**

The discovery of antibiotics in 1928 [1] revolutionized the practice of medicine, which are useful in treating infectious diseases, both in outdoor and indoor patients. Initial enthusiasm however, was quickly tempered by the emergence of pathogens that became resistant to these agents [2]. Resistant bacteria are emerging, as a threat to the favorable outcome of common infections in community and hospital settings.

$\beta$ -lactam antibiotics are among the safest & most frequently prescribed antimicrobial agents all over the world in treating Gram positive and Gram negative infec-

tions [3]. Production of  $\beta$ -lactamases is the most common mechanism of the bacterial resistant for these antibiotics. These enzymes are numerous and are plasmid mediated, capable of hydrolyzing and inactivating a wide variety of  $\beta$ -lactam antibiotics, including third generation Cephalosporins, Penicillin & Azteronam [4]. ESBL producing Gram Negative bacteria are increasingly being associated with hospital infections. They can be found in variety of Enterobacteriaceae species. Majority of ESBL producing strains are *K. pneumoniae*, *K. oxytoca* and *E.coli* [5].

The continued emergence of ESBLs presents diagnostic challenges to the clinical microbiology laboratories, which should be aware of the need for their detection by

accurately identifying the enzymes in clinical isolates. Appropriate antimicrobial selection, surveillance systems & effective infection control procedures are the key partners in their management. Considering the above facts, ESBL detection should reach the clinician as early as possible to enable him to treat the critical patients, favorably. This is a modest attempt to evaluate a simple, cost effective & quick method of detection of ESBL in Clinical isolates of E.coli and Klebsiella species in our hospital laboratory.

## Materials and Method

The present study was carried out in Department of Microbiology, R.N.T. Medical College, Udaipur, Rajasthan. 200 screened isolates of E.coli and Klebsiella species from various clinical samples such as pus, urine, sputum, blood, CSF, ear discharge and pleural fluid, were included in the study. The clinical samples were processed by plating on blood agar and MacConkey agar [6].

All the isolates were identified using standard biochemical tests [6]. Total 200 screened isolates of E.coli and Klebsiella species were tested for antimicrobial susceptibility by Disc diffusion technique (Kirby- Bauer Method) according to CLSI guidelines [7].

Antibiotic discs were used were manufactured by Hi-Media.

Other samples	Urine Samples
Ceftazidime (Ca) 30 $\mu$ g	Ceftazidime (Ca) 30 $\mu$ g
Ceftazidime (Ca) 30 $\mu$ g	Norfloxacin (Nx) 10 $\mu$ g
Amikacin (AK) 30 $\mu$ g	Nitrofurantion (NF) 300 $\mu$ g
Ciprofloxacin (CF) 5 $\mu$ g	Amikacin (AK) 30 $\mu$ g

### Preparation of Plates

Muller Hinton agar plates were used for the test & plates were stored at 4<sup>0</sup>C and used within one week of preparation. Before inoculation, plates were dried so that there were no droplets of moisture on the agar surface.

### Inoculum:

Direct colony suspension, equivalent to 0.5 McFarland standard was used [11].

### Inoculation

A Sterile cotton swab was dipped in suspension and surplus removed by rotation of swab against the Side of tube.

The plate was inoculated by even streaking of swab over the entire surface.

The results were interpreted as per the Criteria of CLSI guidelines. Isolates with resistance or with decreased susceptibility (intermediate by CLSI (criteria) to third generation cephalosporin were selected for ESBL production [7, 8].

ESBL detection was done by Double Disk Synergy disk diffusion test & Inhibitor Potentiated disk diffusion test.

### Double Disk Synergy Test (DDST)

Muller-Hinton agar plates were prepared and inoculated with standardized inoculums (corresponding to 0.5 McFarland standard) to form a lawn culture. With a sterile forceps, a disk of amoxicillin/clavulanic acid (20  $\mu$ g /10 $\mu$ g) was placed in the centre of the plate. Then giving a centre to centre distance of 20 mm around the amoxy-clav disk the Cefotaxime (30  $\mu$ g), Ceftriaxone(30 $\mu$ g) and Cef-tazidime (30 $\mu$ g) disks were applied. This distance was found to give the best results for detection of ESBLs in our laboratory. The plates were incubated at 37 $^{\circ}$ C in incubator for overnight incubation.

### Observation and interpretation

Strain interpreted as ESBL producer when –

- A- Irrespective of the individual zone size, the zone size around the test antibiotics (3GC) was extended on the side nearest the amoxicillin / Clavulanic acid disk. An increase in zone of inhibition of > 2.5 mm on one side was considering/ considered significant.
- B- Antibiotic disk was not inhibitory alone but bacterial growth was also inhibited between the two disks.
- C. Bulging or broadening of the inhibitory zone between the 3 GC disk and the disk of amoxicillin/ Clavulanic acid. Non- ESBL producing strain did not show synergy as demonstrated by any of these patterns. E.coli ATCC 25922 was used as the negative control and Klebsiella pneumoniae ATCC 700603 obtained from JIPMER Pondicherry were used as the positive control [9, 10, and 11].

### Inhibitor Potentiated disk diffusion test

Muller- Hinton agar plates were prepared and inoculated with a standardized inoculum (corresponding to 0.5 McFarland's standard) to form a lawn culture. Using sterile forcep disks of Cefotaxime (Ce) and Cefotaxime/ Clavulanic acid (Ca/C) and disks of Ceftazidime (Ca) and Cef-tazidime/ Clavulanic acid (Ca/C) were placed, by keeping a 15 mm center to center distance. Plates were incubated at 37 $^{\circ}$ C in incubator for overnight[9,12,13,14].

### Interpretation

A > 5 mm – increase in the Zone diameter for either of the (3 GC) antimicrobial agent tested in combination with Clavulanic acid versus its zone when tested alone indicated ESBL production.

### Quality Control

The negative control i.e. E.coli ATCC 25922 shows a < 2 mm increase in zone diameter for antimicrobial agent tested alone versus its zone when tested in combination with Clavulanic acid. The positive control i.e. Klebsiella pneumoniae ATCC 700603 shows a > 5 mm increase in Ceftazidime zone diameter and a > 3 mm increase in Cefotaxime zone diameter. [7, 9, 10].

### Results and Observation

The present study was conducted on 200 Screened isolates of E.coli & Klebsiella species, obtained from 3146 various clinical samples like blood, urine, pus, sputum, vaginal secretion, body fluids etc. Of the 200 screened isolates of E.coli & Klebsiella species, 58.5% (117) were identified as E.coli. Of the 117 isolates of E.coli the rate of isolation from various clinical samples was 65.8% (77) from urine, 17.1% (20) from Pus, 11.1% (13) from Sputum, 4.2% (5) from vaginal secretion, 0.9% (1) each from stool & body fluids. 41.5 % (83) Klebsiella species were identified the incidence of K. pneumoniae isolates was 27 % (54) & K. oxytoca was 14.5% (29) [Table 11].

Among the 83 isolates of Klebsiella species 27.7% (23) & 15.6 % (13) K. pneumoniae & K.oxytoca respectively were obtained from sputum subsequently, 14.4% (12) & 15.6 % (13) from Pus, 14.4.% (12) & 2.4% (2) from urine, 1.2%(1) each from vaginal secretion, 7.2 % (6) from various body fluids. The maximum resistance among E. coli and Klebsiella species isolates was observed against Cefpodoxime 100% & Cefotaxime 73.5% for both followed by other antimicrobial agents as Ceftazidime 77.0% & 69.9% , Ceftriaxone 74.4.% & 72.3 % & Aztreonam 65.0% & 63.9% respectively . Overall 200 isolates showed resistance to at least one of the 3GC or Aztreonam [Table 1.].

The incidence of ESBLs among E.coli isolates is 48.7% and among Klebsiella species is 34.9%. The incidence of ESBLs in K. pneumoniae isolates is 35.1 % & K. oxytoca is 34.4 %. ESBL positivity among 117 E.coli isolates was 39.3% (46) & among 83 Klebsiella species was 32.5% (29). Among the Klebsiella species, Klebsiella pneumoniae and Klebsiella oxytoca isolates shows ESBL positivity rate was 31.4% (17) & 34.4% (10) respectively [Table 2].

92.6 % of Klebsiella spp. and 89.1 % of E.coli showed synergy between Ceftazidime and clavulanate in the DDST. Where as Cefotaxime showed synergy 66.7% & 71.7% and Ceftriaxone showed 88.8 % & 71.7 % Klebsiella species and E.coli isolates respectively [Table 3].

By the IPDDT, The incidence of ESBLs among E.coli and Klebsiella species isolates was 40.1 % (47) & 27.7 % (23) when Ceftazidime and combination Ceftazidime with Clavulanic acid tested respectively, and total incidence of ESBLs was 35% (70) with Ca/Ca/C where as Cefotaxime and combination Cefotaxime with Clavulanic acid was tested, the percentage of ESBLs positive E.Coli were 43.5 % (51) & that of Klebsiella spp. is 28.9 % (24). The Total incidence of ESBLs was 37.5% (75) with Ce/ Ce/C. Thus, overall incidence of ESBLs among E.coli and Klebsiella species isolates was 44.4 % (52) and 36.1 % (30) respectively, when tested with Ca Vs Ca/C & Ce Vs Ce/C. The total incidence of ESBLs was 41.0% (82) with Ca/ Ca/C & Ce/Ce/C [Table 4].

Inhibitory Potentiated disk diffusion test detected an additional 4.5% (9) ESBL isolates than the DDST [Table 5].

The Percentage of ESBL Positive E.Coli isolated from Medicine was 56.1 %, Surgery 21.0%, Gynae. and Obstet. 17.5%, ICU 3.4%, and Pediatrics 1.7 %. Whereas none of the ESBL producing E.Coli was isolated from TB & Chest, ENT, Psychiatry, burns & Skin wards [Table 6].

The Percentage of ESBL positive Klebsiella species isolated from various clinical wards was Medicine 44.8 %, Surgery 31.0%, TB & chest 20.6% and Gynae. & obst. 3.4% Whereas none of the ESBL producing Klebsiella species isolated from Paediatrics, I.C.U. Burns, ENT, Psychiatry & Skin wards [Table 7].

**Table 1.** Antimicrobial sensitivity pattern of E.coli and Klebsiella species to 3<sup>rd</sup> generation cephalosporins and aztreonam: Initial screen test for detection of possible ESBLs produces

Antibiotic Disks	E.coli (n=117)				Klebsiella species n (83)			
	Resistant		Sensitive		Resistant		Sensitive	
	No	%	No	%	No	%	No	%
Ceftazidime	90	77	27	23	58	69.9	25	30

Detection of extended-spectrum  $\beta$ -lactamases in clinical isolates

Cefotaxime	86	73.5	31	26.5	61	73.5	22	26.5
Ceftriaxone	87	74.4	30	25.6	60	72.3	23	27.7
Cefpodoxime	117	100	0	0	83	100	0	0
Aztreonam	76	65	41	35	53	63.9	30	36.1

**Table 2.** Incidence of ESBLs: in *E.coli* & *Klebsiella* species isolates.

Isolates	ESBL	Non- ESBL
<i>E.coli</i> (n=117)	57(48.7%)	60(51.3%)
<i>Klebsiella pneumoniae</i> (n=54)	19 (35.1%)	35(64.9%)
<i>Klebsiella oxytoca</i> (n=29)	10 (34.4%)	19(65.6%)
Total (n=200)	86 (43%)	114 (57%)

**Table 3.** Percentage of ESBL positive isolates showing synergy between Clavulanic acid and individual antibiotics in the double disk synergy test (DDST). 3 GC

Organism	No. of ESBL Positive by DDST	3GC Antibiotics					
		Ceftazidime		Cefotaxime		Ceftriaxone	
		No	%	No	%	No	%
<i>E.Coli</i>	46	41	89.1	33	71.7	33	71.7
<i>Klebsiella</i>	27	25	92.6	18	66.7	24	88.8
Total	73	66	90.4	51	69.8	57	78.1

**Table 4.** Percentage of ESBLs by – Inhibitory Potentiated disk diffusion test (IPDDT).

Organism	Total Tested	Inhibitor Potentiated disk diffusion test				Ca Vs Ca/C + Ce Vs Ce/C	
		Ca Vs Ca/C		Ce Vs Ce/C		No	%
		No	%	No	%		
<i>E.Coli</i>	117	47	40.1	51	43.5	52	44.4
<i>Klebsiella</i> Species	83	23	27.7	24	28.9	30	36.1
Total	200	70	35.0	75	37.5	82	41.0

**Table 5.** Comparative study of different methods for detection of ESBL positive isolates.

Organism	Total Number Tested	Double Disk Synergy test (DDST)		Inhibitor potentiated disk diffusion test ( IPDDT)	
		No (+ve)	%	No. (+ve)	%
		<i>E.coli</i>	117	46	39.3
<i>Klebsiella</i> species	83	27	32.5	30	36.1
Total	200	73	36.5	82	41.0

**Table 6.** Distribution of ESBLs positive *E.coli* isolates in different departments (n=57).

Department	Medicine	Surgery	Gynae. & Obst.	TB & Chest	Paediatrics	I.C.U	Burns	E.N.T	Psychiatry	Skin & V.D
No. of <i>E.Coli</i>	62	30	13	2	1	4	-	1	1	3

ESBL positive E.coli	32	12	10	-	1	2	-	-	-	-
% of ESBL positive E.coli	56.1	21.1	17.6	-	1.7	3.5	-	-	-	-

**Table 7.** Distribution of ESBL positive Klebsiella species isolated in different departments (n= 29).

Department	Medicine	Surgery	Gynae.& Obst.	TB & Chest	Paediatrics	I.C.U	Burns	E.N.T	Psychiatry	Skin & V.D
No. of Klebsiella sp.	34	22	3	16	-	5	1	2	-	-
ESBL positive Klebsiella species	13	9	1	6	-	-	-	-	-	-
% of ESBL positive Klebsiella species	44.8	31.1	3.4	20.7	-	-	-	-	-	-

## Discussion

ESBLs are the main cause of resistance to beta-lactam antibiotics in E.coli and Klebsiella. Due to the clinical importance of the detection of ESBLs, screening and confirmatory methods have been routinely used to investigate the production of these enzymes in E.coli & Klebsiella species. As their occurrence has been increasing, it becomes essential to evaluate their occurrence in this population. The present study was conducted on 200 screened isolates of E.coli and Klebsiella species obtained from 3146 various clinical samples received at the Department of Microbiology, R.N.T. Medical College, Udaipur, Rajasthan. In the present study out of 200 screened isolates 58.5% (117) were identified as E.coli & 41.5% (83) were Klebsiella species. The maximum resistance among E.coli and Klebsiella species isolates was observed against cefpodoxime 100% and cefotaxime 73.5% respectively. Overall 200 isolates showed resistance to at least one of the 3 GC or Aztreonam. Isolates with resistance or decreased susceptibility (intermediate by NCCLS criteria) to third generation Cephalosporin were selected for ESBL production & this showed the incidence of ESBLs among E.coli isolates is 48.7% and among Klebsiella pneumoniae (35.1%) & Klebsiella oxytoca (34.4%). Percentage of ESBLs positive isolates showing synergy between Clavulanic acid and Ceftazidime, Cefotaxime & Ceftriaxone individually antibiotics in Double disk synergy test were 92.6%, 66.7% and 88.8% for Klebsiella species & 89.1%, 71.7% and 71.7% for E.coli respectively. This is higher than the reported figures of E.coli & Klebsiella spp. in 2.2% & 6.6% respectively in U.S.A., in Canada 2.7% & 6.2% respectively [15,16] & in India 24.7% & 38.5% respectively[14]. In Asia, National surveys have indicated the presence of ESBLs in 5-8 % of E.coli iso-

lates from Korea, Japan, Malaysia & Singapore with higher rates of up to 24% for other Asian countries [17,18,19]. ESBL production in Klebsiella has also been reported to be as low as 5% in Japan & Australia with higher rates of 20-5-% in other parts of the continent [12, 13].

In the present study, from the Inhibitory Potentiated disk diffusion test (IPDDT), the incidence of ESBLs among E.Coli and Klebsiella species isolates was 40.1% (47) & (27.7%) (23), when Ceftazidime and combination Ceftazidime with Clavulanic acid tested respectively. Total incidence of ESBLs was 35% (70) with Ca/CaC where as Cefotaxime and combination of Cefotaxime with Clavulanic acid was tested, the percentage of ESBLs positive E. coli were 43.5% (51) & that of Klebsiella species is 28.9% (24). The total incidence of ESBLs was 37.5(75) with Ce/CeC. Thus, overall incidence of ESBLs among E.coli and Klebsiella species isolates was 44.4% (52) and 36.1% (30) respectively when tested with CaVs Ca/C & Ce Vs Ce/C. The total incidence of ESBLs was 41.0% (82) with Ca/ CaC & Ce/CeC. Comparative study of this two method shows that, Inhibitory Potentiated disk diffusion test detected an additional 4.5% (9) ESBL isolates. A predominance of either K.pneumoniae or E.coli has often been reported among the ESBL isolates identified in different geographical regions. A prevalence of ESBL-producing K.pneumoniae versus ESBLs-producing E.coli (70% v/s 28.8%) has been reported in Pakistan [14,19,20].

From our findings, the percentage of ESBL positive E.coli isolated from Medicine was 56%, Surgery 21.0%, Gynae. and obstet. 17.5%, I.C.U. 3.4%, and Paediatrics 1.7%. Whereas none of the ESBL producing E.coli was

isolated from TB & Chest, E.N.T. Psychiatry, burn & Skin wards. The percentage of ESBLs positive Klebsiella species isolated from various clinical wards was medicine 44.8%, Surgery 31.0% , TB & Chest 20.6% , and Gynae. & obst. 3.4%. Whereas none of the ESBL producing Klebsiella species isolated from Pediatrics, I.C.U., Burns, E.N.T. Psychiatry & Skin wards.

Most of the ESBL isolates were from Medicine and Surgery wards in the present study. This may be due to fact that all the patients who underwent surgery were catheterized and given broad spectrum antibiotics preoperatively. As the patients have undergone surgery duration of the hospital stay may be the predisposing factor for these ESBL producing organisms.

Equipment such as artificial ventilation apparatus, catheters, cannula and nursing care work load are likely risk factor. Mathur et al [5] from New Delhi have also documented 50% of ESBL production from surgical wards & 54% from medical wards [21,22,23].

## Conclusions

The present study is preliminary attempt to evaluate the ESBL producing E.coli & Klebsiella species from various clinical samples. ESBL production has been observed in large percentage of E.coli and Klebsiella isolates. ESBL producing E.coli and Klebsiella species infections have a significant impact on several important clinical outcomes and efforts to control outbreaks of such infections should emphasize judicious use of all antibiotics as well as barrier precautions to reduce spread.

## References

1. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-12.
2. Siegel JD, Rhinehart E, Jackson M, Chiarello L. Health Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in healthcare settings 2006. Available from:<http://www.cdc.gov/ncidod/dhqp/pdf/ar/MDROGuideline2006.pdf> [accessed on 2009 Feb 23].
3. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
4. Wayne PA. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. Clin Lab Standards Inst 2008. M100-S18.
5. Babini GS, Livermore DM. Antimicrobial resistance amongst *Klebsiella* spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000;45:183-9.
6. Moland ES, Black JA, Ourada J, Reisbig MD, Hanson ND, Thomson KS. Occurrence of newer beta-lactamases in *Klebsiella pneumoniae* isolates from 24 US hospitals. Antimicrob Agents Chemother 2002;46:3837-42.
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Approved standards M2-A7, eighteenth informational supplement. CLSI document M100-S18. Wayne,PA.2006.
8. Mathai D, et al. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents recent clinical isolates from india: a survey of ten medical centre laboratories. Diag Microbial infect Dis 2002;44:367-377.
9. Yu Y, Zhou W, Chen Y, Ding Y, Ma Y. Epidemiological and antibiotic resistant study on extended-spectrum betalactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in Zhejiang Province. Chin Med J (Engl) 2002;115:1479-82.
10. Babypadmini S, Appalaraju B. Extended spectrum  $\beta$ -lactamases in urinary isolates of *Escherichia coli* and *Klebsiella pneumoniae*-prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol 2004;22:172-4.
11. Tankhiwale SS, Jalgaonkar SV, Ahamad S, Hassani U. Evaluation of extended spectrum beta lactamase in urinary isolates. Indian J Med Res 2004;120:553-6.
12. Medeiros AA. Evolution and dissemination of beta-lactam antibiotics accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 1997;24Suppl1:S19-45.
13. Mathai D, et al. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents recent clinical isolates from india: a survey of ten medical centre laboratories. Diag Microbial infect Dis 2002;44:367-377.
14. Mathai E Nosocomial bactremia and antimicrobial resistance in intensive care units. Ind J Med Res 2005;122:285-7.
15. Johann D, Pitout D, Kevin B Laupland Extended-spectrum B-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-66.
16. Philip J Turner. Extended Spectrum B-Lactamases. Clin Infect Dis 2005;41:S273-75.
17. David L Paterson and Robert A Bonomo. Extended-Spectrum B-Lactamases: A Clinical update. Clin Microbiol Rev 2005;18:657-686.
18. Mario Tumbarello, Terasa Spanu, Maurizio Sanguinetti et al. Bloodstream infections caused by Extended-Spectrum B-Lactamase producing *Klebsiella pneumoniae*: Risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006;50:498-504.

19. Michael A Pfaller, John Segreti. Overview of the epidemiological profile and laboratory detection of Extended Spectrum B-Lactamases. *Clin Infect Dis* 2006;42:S153-63.
20. Varshs Gupta. An update on newer B-Lactamases. *Indian J Med Res* 2007;126:417-427.
21. Su Young Lee, Srividya Kotapati, Joseph L Kuti et al. Impact of Extended-Spectrum B-Lactamase-producing *Echerichia coli* and *Klebsiella* species on clinical outcomes and hospital costs: A matched cohort study. *Infect Control Hosp Epidemiol* 2006;27:1226-1232.
22. Mitchell J Schwaber, Shiri Navon-Venezia, Keith S Kaye et al. Clinical and economic impact of bacteremia with extended spectrum-B-Lactamase-producing *Enterobacteriaceae*. *Antimicrob Agents Chemother* 2006; 1257-1262.
23. Ebbing Lautenbach, Jean Baldus Patel, Warren B Bilker. Extended-Spectrum B-Lactamase producing *Echerichia coli* and *Klebsiella pneumoniae*: Risk factors for infection and impact of resistance on outcomes. *Clin Infect Dis* 2001;32:1162-71.
24. Bonnet R. Growing group of Extended-Spectrum B-Lactamases: the CTX-M enzymes. *Antimicrob Agents Chemother* 2004; 48: 1-14.

**Correspondence to:**

Sushil Kumar Sahu  
Department of Microbiology  
R.N.T. Medical college  
Udaipur, Rajasthan

